Technology
Health
Biotechnology
Cellectar Biosciences
$2.009876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.
$2.00
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
+$0.11 (5.53%) Today
-$0.10 (-4.76%) After Hours
Why Robinhood?
You can buy or sell CLRB and other stocks, options, ETFs, and crypto commission-free!
About
Cellectar BioSciences, Inc. engages in the development of phospholipid drug conjugates (PDCs) for the treatment and imaging of cancer. Its portfolio includes CLR 131, which seeks to treat relapse or refractory multiple myeloma; CLR 125, which intends to treat micro metastatic disease; CLR 124 which could detects tumors and metastases in a broad range of cancers; and CLR 1502, a cancer-targeting near-infrared-fluorophore optical imaging PDC for intraoperative tumor and tumor margin illumination. Read More The company was founded in June,1996 and is headquartered in Florham Park, NJ.
Employees
7
Headquarters
Florham Park, New Jersey
Founded
1996
Market Cap
10.68M
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
263.00K
High Today
$2.11
Low Today
$1.92
Open Price
$1.99
Volume
249.08K
52 Week High
$12.76
52 Week Low
$1.22
Collections
Technology
Health
Biotechnology
Cancer Prevention
Medical
2018 IPO
US
North America
News
Seeking AlphaMay 16
Cellectar down 25% on $10M capital raise
Cellectar Biosciences (CLRB -25.4% ) obliterates yesterday's 24% spike with its $10M direct stock offering to institutional investors.
Seeking AlphaMay 13
Cellectar's CLR 131 Fast Track'd for multiple myeloma; shares up 6%
Thinly traded nano cap Cellectar Biosciences (CLRB +5.6% ) is up on more than a 4x surge in volume on the heels of Fast Track status in the U.S. for lead candidate CLR 131 for the fourth line (or greater) treatment of relapsed/refractory multiple myeloma.
Yahoo FinanceMay 13
Cellectar Receives FDA Fast Track Designation for CLR 131 in Relapsed or Refractory Multiple Myeloma
Designation could accelerate CLR 131 development and underscores the need for new treatments FLORHAM PARK, N.J., May 13, 2019 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for CLR 131 in fourth line or later relapse/refractory multiple myeloma. CLR 131 is the ...
Price Paid on Robinhood
48% Lower
Right Now
52 Week Low
$1.22
Average Price Paid
$3.88
52 Week High
$12.76
Earnings
-$2.10
-$1.38
-$0.66
$0.06
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
—
Actual
Expected Aug 8, Pre-Market